Question special
Residents and Fellow

The subgroup of patients with coagulopathy is significantly more represented (p= 0.02) in the cohort that received the PPI. I think that this difference in PPI treatment versus the placebo could have affected both the primary outcome and the incidence of important GI bleeding (as a secondary outcome). Would like to hear your perspectives.